✦ LIBER ✦

5057 Efficacy of combination treatment with epirubicin (EPl) plus docetaxel (DOC) in advanced breast cancer

✍ Scribed by Y. Hata; M. Takahashi; H. Takahashi; M. Hosoda; K. Taguchi; M. Tamura; N. Tomioka; S. Ohsawa; T. Nakagawa; S. Matsuoka

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of advanced, refractory breast

✍ Werner Kwasny; Gabriela Kornek; Karin Haider; Julia Valencak; Herbert Ulrich-Pur 📂 Article 📅 2000 🏛 Springer US 🌐 English ⚖ 52 KB

5174 Predictive factors of response to n

✍ Strada, M.R.; Frascaroli, M.; Palumbo, R.; Bernardo, A.; Villani, L.; Scelsi, M. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Efficacy and tolerability of combination

✍ E Szombara; I Glogowska; R Sienkiewicz-Kozlowska; T Pienkowski; S Jaczewska 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 178 KB

A multicenter phase I–II study of doceta

✍ Tryfonidis, K.; Boukovinas, I.; Xenidis, N.; Christophyllakis, C.; Papakotoulas, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 348 KB

HER-2, p53, p21 and hormonal receptors p

✍ Daniel G Tiezzi; Jurandyr M Andrade; Alfredo Ribeiro-Silva; Fábio E Zola; Heitor 📂 Article 📅 2007 🏛 BioMed Central 🌐 English ⚖ 353 KB

Multicenter phase II study of trastuzuma

✍ M. Venturini; C. Bighin; S. Monfardini; F. Cappuzzo; N. Olmeo; A. Durando; F. Pu 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 218 KB